Get the Stockscreener App
2.02
10.22%
-0.23
After Hours:
2.02
Pluri Inc stock is traded at $2.02, with a volume of 40,297.
It is down -10.22% in the last 24 hours and down -35.26% over the past month.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
See More
Previous Close:
$2.25
Open:
$2.25
24h Volume:
40,297
Relative Volume:
3.82
Market Cap:
$21.79M
Revenue:
$1.08M
Net Income/Loss:
$-26.95M
P/E Ratio:
-0.7035
EPS:
-2.8712
Net Cash Flow:
$-21.69M
1W Performance:
-10.22%
1M Performance:
-35.26%
6M Performance:
-41.45%
1Y Performance:
-53.13%
1-Day Range:
$2.00
$2.43
1-Week Range:
$2.00
$2.43
52-Week Range:
$2.00
$5.96
Pluri Inc Stock (PLUR) Company Profile
Name
Pluri Inc
Sector
Industry
Phone
972-74-710-7171
Address
MATAM ADVANCED TECHNOLOGY PARK, HAIFA
Compare PLUR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLUR
Pluri Inc
|
2.02 | 21.79M | 1.08M | -26.95M | -21.69M | -2.8712 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pluri Inc Stock (PLUR) Latest News
Pluri Inc (PLUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pluri Inc (PLUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pluri Inc (PLUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pluri Inc (PLUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pluri Inc (PLUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pluri Inc (PLUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pluri Inc (PLUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pluri Inc (PLUR) Institutional Confidence - TradingKey
Pluri Inc. (PLUR) Edges Higher as Stock Nears Key Resistance LevelMarket Leader Picks - newsline.com
Pluri Inc. Q1 2026 Earnings: EPS Misses as Pre-Revenue Biotech Continues Pipeline DevelopmentReturn On Assets - newsline.com
PLUR Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains AbsentProfit Guidance Range - newsline.com
UnitedHealth Raises Dividend 5% Amid Rising Healthcare CostsEarnings Decline Risk - newsline.com
Made Scientific, Pluristyx launch development and manufacturing partnership - ROI-NJ
Made Scientific and Pluristyx Launch Integrated iPSC Development & Manufacturing Partnership to Advance Next-Generation iPSC-derived Cell Therapies - The Malaysian Reserve
Pluri subsidiary completes U.S. cosmetic listing for two products By Investing.com - Investing.com Nigeria
Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing - The Manila Times
Pluri subsidiary completes U.S. cosmetic listing for two products - Investing.com
Two new skin treatments target $90B U.S. aesthetics market - Stock Titan
Pluri's Leap from Lab to Luxury: A High-Stakes Bet on Regenerative Beauty - BriefGlance
Pluri in Good-Faith Talks on EIB Loan Resolution - TipRanks
Pluri Inc. and European Investment Bank continue loan discussions, no enforcement action expected before July - Investing.com
Pluri Biotech Ltd., Pluristem Gmbh, and Pluri Inc. Remain in Constructive Discussions with European Investment Bank Regarding EUR 20 Million Loan - marketscreener.com
Pluri (NASDAQ: PLUR) negotiates with European Investment Bank over €20M loan due 2026 - Stock Titan
Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In - Insider Monkey
7 Best Lab-Grown Meat Stocks to Invest In - Insider Monkey
Pluri Inc. (PLUR) Gains 4.6%, Approaches Resistance at $2.52Breadth Thrust - The Legal Advocate
Plurilock Security Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Plurilock Security Inc.: Plurilock Security Inc. Reports First Quarter 2026 Financial Results - FinanzNachrichten.de
Pluri Insider Ups Holding During Year - Yahoo Finance
Pluri Inc. (PLUR) Posts Modest Gain as Stock Holds Above Key SupportAdaptive Moving Average - newsline.com
Pluri Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Lack of Revenue DisclosureManagement Guidance Update - The Legal Advocate
Pluri Inc. (PLUR) Climbs 3.22% as Shares Test Resistance Near $2.49Community Momentum Stocks - Newser
Pluri Inc. (PLUR) Q1 2026 Earnings: Wider-than-Expected Loss Sends Shares LowerRetail Trader Picks - Newser
This Pluri Insider Increased Their Holding In The Last Year - simplywall.st
Pluri: Fiscal Q3 Earnings Snapshot - marketscreener.com
Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
Pluri Inc. (NASDAQ: PLUR) faces going concern risk amid EIB debt wall - Stock Titan
Number of shareholders of Pluri Inc. – NASDAQ:PLUR - TradingView
PLURI INC (PLUR) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - TradingKey
MSN Money - MSN
Pluri (PLUR) Earnings Date and Reports 2026 $PLUR - MarketBeat
MSN - MSN
PLUR Pluri reports wider than projected Q1 2026 loss while shares notch small gains in today’s trading session.Competitive Risk - newser.com
Insider-backed Chutzpah Holdings (NASDAQ: PLUR) buys 625K shares and warrants - Stock Titan
Pluri Inc Stock (PLUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):